Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Barr Generic Premarin Development Plan Includes Exclusive Supply Deal

  • News

Executive Summary

Barr anticipates that its exclusive supply agreement with Natural Biologics will permit pricing of its Premarin generic as a single-source generic

You may also be interested in...



Barr Still Betting On Generic Premarin; May Seek Other Estrogen Suppliers

Barr may pursue other raw material suppliers for generic versions of Wyeth's conjugated estrogens product Premarin if a recent court ruling against Barr's supplier Natural Biologics is not overturned on appeal

Barr Still Betting On Generic Premarin; May Seek Other Estrogen Suppliers

Barr may pursue other raw material suppliers for generic versions of Wyeth's conjugated estrogens product Premarin if a recent court ruling against Barr's supplier Natural Biologics is not overturned on appeal

Barr Barred From Premarin Equine-Based Generics; ANDA Status Under Review

Barr Labs will meet with FDA to discuss the status of its conjugated estrogens ANDA following a district court decision barring the company from using Natural Biologics' raw material for an "AB"-rated generic

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

See All
UsernamePublicRestriction

Register

PS039429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By